SEC Form 4 · accession 0000899243-17-024249
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard J Hawkins
Director
Period of report
Oct 13, 2017
Accepted (ET)
Oct 16, 2017 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 13, 2017 | D | 24,363 | $11.18 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F1 | $6.04 | Oct 13, 2017 | D | 30,000 | D | — | Jun 30, 2021 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F3 | $6.78 | Oct 13, 2017 | D | 30,000 | D | — | Jun 7, 2022 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F4 | $5.13 | Oct 13, 2017 | D | 30,000 | D | — | Jun 27, 2023 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F5 | $5.10 | Oct 13, 2017 | D | 30,000 | D | — | Jun 12, 2024 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F6 | $9.15 | Oct 13, 2017 | D | 30,000 | D | — | Jun 11, 2025 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F7 | $10.90 | Oct 13, 2017 | D | 30,000 | D | — | Jun 8, 2027 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012.
- F2The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- F3Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013.
- F4Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.
- F5Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.
- F6Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
- F7Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.